Take a closer look at treatment outcomes and the types of patients who could benefit from ▼Beovu® (brolucizumab).
Treatment-naïve patient from the HAWK trial*1
Age: 89, Sex: Female, Race: Caucasian
Newly diagnosed female with wet AMD*1
Age: 87, Sex: Female, Race: Caucasian
Real-world wet AMD patient who switched from another anti-VEGF*1
Age: 75, Sex: Female, Race: Caucasian
*Certain identifiable information has been modified. Case is provided by treating physician and is not representative of whole patient population.
AMD, age-related macular degeneration; VEGF, vascular endothelial growth factor.
- Novartis data on file. BRODOF21-002, 2021.